TOFAJIN-ER 11 Tablets

Edward Young Labs presents Tofajin-ER 11, composed of Tofacitinib Extended Release Tablets 11mg. As part of the rheumatology and immunology segment, this extended release formulation is manufactured with advanced processes, ensuring quality, stability, and trusted delivery for distributors.

With a focus on excellence, Tofajin-ER 11 is packed in hygienic conditions and designed to deliver a stable formulation that meets industry expectations. It stands as a trusted product choice for healthcare professionals and distributors seeking quality and consistency.

Edward Young Labs presents Tofajin-ER 11, composed of Tofacitinib Extended Release Tablets 11mg. Positioned in the rheumatology and immunology segment, this formulation is developed through advanced pharmaceutical processes to deliver consistency, stability, and trusted results.

The “ER” in Tofajin-ER 11 stands for Extended Release, which is a specialized technology designed to release the active ingredient gradually over an extended period. Unlike immediate-release tablets that deliver the full dose at once, extended release formulations allow the medicine to be absorbed slowly and steadily in the body. This helps in maintaining uniform levels of the active compound for a longer duration, reducing fluctuations and ensuring more predictable outcomes.

By incorporating extended release technology, Tofajin-ER 11 offers several practical advantages, including convenience of dosing, enhanced patient compliance, and sustained effectiveness. Manufactured under rigorous quality controls and packaged hygienically, Edward Young Labs ensures that every tablet meets high industry benchmarks, making it a dependable choice for distributors and healthcare professionals.